AstraZeneca to invest $2bn in Summit for ADC combination therapies

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types. AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. AstraZeneca and Summit agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin. Credit: Jose Eduardo Rubio / Shutterstock.com. AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and antibody-drug conjugates (ADCs) across multiple tumour types. Under the transaction, AstraZeneca…

Salong Debbarma · 2026-09-29

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Source: Pharmaceutical Technology